PET Scan in Gastro Oesophageal Tumour Staging

Positron Emission Tomography (PET) scans, often using the tracer fluorodeoxyglucose (FDG), are crucial imaging tools in the preoperative staging of gastro-oesophageal tumours. They help determine the extent of the cancer and guide treatment planning.

Detecting Distant Metastatic Disease

The primary role of PET scanning in this context is to identify distant metastatic disease. This refers to cancer that has spread from the original tumour site (in the oesophagus or stomach) to other parts of the body, such as the liver, lungs, or bones. Detecting distant metastases is critical because it often changes the treatment strategy from potentially curative surgery to palliative care or systemic therapy.

Evaluating Other Aspects of Spread

• Local Spread: While PET can provide some information about the local invasion of the tumour into adjacent structures, other imaging modalities like CT or MRI are often more detailed for assessing this specific aspect.
• Lymph Node Status: PET can help identify enlarged or metabolically active lymph nodes, suggesting potential metastasis. However, distinguishing between reactive inflammation and actual cancer spread in lymph nodes can sometimes be challenging with PET alone, especially for smaller nodes.
• Extension into Stomach: Assessing the direct extension of an oesophageal tumour into the stomach, or vice versa for a gastric tumour, is often better evaluated using CT or endoscopy.

Conclusion

PET's strength in staging gastro-oesophageal cancer lies in its ability to detect occult (hidden) distant metastases that might not be apparent on conventional imaging. Therefore, its main purpose is the detection of distant metastatic disease.